ObesityNCT07640139
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
An observational study of Obesity, run by Indiana University at 1 site in United States.
Trial summary
The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 18 to 64 years
- Conditions the study is for
- Obesity
- What is being tested?
- Incretin-based therapies (GLP-1 and GLP-1/GIP)
- How many people
- 125,000 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jan 2026to 31 Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- No healthy volunteers
- Adult
Study population: Working-age adults and their adult dependents who receive their health insurance coverage from participating, self-insured Indiana employers.
The study cohort is limited to employees and adult dependents aged 18-64 who receive their health insurance coverage from self-insured Indiana employers that agree to participate in the study.
To be included in the study, the individuals must:
- Be an Indiana resident;
- Have health insurance benefits provided by participating employers (includes employees and dependents);
- Be between the ages of 18 and 64;
- Meet the eligibility criteria for an obesity medication prescription:
- BMI of ≥ 30 (obesity) or
- BMI of ≥ 25 (overweight) and at least one body weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). If the prescribing eligibility criteria are updated in the future, we will update accordingly.
- Individuals must have at least 6 months of enrollment prior to study inclusion (i.e., prior to the index date), though we may use additional pre-treatment data if available.
An individual who meets any of the following criteria will be excluded from participation in the cohort:
- Has a condition associated with weight loss: a diagnosis of cancer (except for non-melanoma skin cancer), pancreatitis, eating disorders (e.g., anorexia nervosa and avoidant restrictive food intake disorder), HIV, unintentional weight loss, or cirrhosis at baseline;
- Has a condition for which obesity medications are contraindicated (for example, medullary thyroid carcinoma, multiple endocrine neoplasia, etc.).
- Receipt of diabetes-indicated incretin-based medications. If an individual has a claim for a related incretin-based therapy diabetes medication (e.g., Mounjaro, Ozempic, Rybelsus, Victoza) without an obesity-medication claim during the study period, the individual will be excluded from analysis.
- Prior bariatric surgery.
- Evidence of prior use of incretin-based obesity medications for weight loss.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers. The main questions it aims to answer are:
- Is obesity medication usage is associated with reduced body mass index (BMI) and weight?
- Is obesity medication usage is associated with reduced utilization of emergency department and inpatient care or obesity-related conditions over time?
- Is obesity medication usage is associated with increased utilization of outpatient care over time?
- Is obesity medication usage is associated with slower growth in direct medical costs over time?
- Is obesity medication usage is associated with improvements in health measures?
- Is obesity medication usage associated with reduced workplace costs?
Read more
Researchers will compare individuals who have prescriptions for obesity medications to those without to see if differences in health and costs of care exist.
The study uses existing medical and pharmacy claims data.
Read the detailed description
Incretin-based therapies that work by mimicking the action of the natural hormone GLP-1 and GLP-1/GIP have garnered the most excitement and demonstrated promising results in the management of obesity. This project seeks to estimate the impact of incretin-based obesity medications on clinical and economic outcomes in real-world settings. It proposes to fill gaps in the current literature by focusing on patients from self-insured organizations, measuring direct and indirect costs, establishing a long-term cohort, and by merging claims with electronic health record (EHR) data for more comprehensive measures.
The impact of incretin-based obesity medications on clinical and economic outcomes will be assessed in a dynamic cohort design. The cohort will be drawn from the employees and their working age dependents of large, self-insured (or "self-funded") organizations in the state of Indiana (i.e., "employers"). Employer organizations agreeing to participate will provide medical and pharmacy claims as well as data on workplace performance (if available) from 2018-2029. The primary exposure of interest is documented receipt of any GLP-1 obesity medication (regardless of manufacturer or brand name). A series of fixed-effects regression models will estimate the association between exposure to incretin-based obesity medications and clinical, utilization, and cost outcomes. This dynamic cohort approach, 1) individuals and participating employer organizations may enter and exit the cohort over time and 2) individuals may switch between on or off exposure over time.
- Conditions
- Obesity
- Being tested
- Incretin-based therapies (GLP-1 and GLP-1/GIP)
- Keywords
- GLP-1, Obesity medications, Incretin-based
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Incretin-based therapies (GLP-1 and GLP-1/GIP)Drug
Also called Zepbound, Tirzepatide, Wegovy, Semaglutide
Documented receipt of any GLP-1 and GLP-1/GIP obesity medication during an observation period.
| Study group | Role | What they receive |
|---|---|---|
| Persistent use of incretin-based obesity medication | Persistent use is defined as continuous treatment with no gaps greater than 60 days between prescription fills. Discontinuation is defined as a gap exceeding 60 days following the expected end date of a prescription fill (based on days' supply). Exposure will be measured longitudinally from the index date until discontinuation or censoring. Days of supply will be calculated from pharmacy claims, and we will account for stockpiling by allowing early refills to extend coverage forward in time. If days' supply is missing, it will be imputed using prescribing guidelines or external data sources. Receives: Drug: Incretin-based therapies (GLP-1 and GLP-1/GIP) | |
| No documented receipt of incretin-based obesity medication during observation period | Working-age adults (age 18 to 64) insured by participating Indiana-based employers that do not use any incretin-based obesity medication for weight loss. Identified by no claim for obesity medications (accounting for days supply and available refills). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in subject body weight.
Measured in pounds.
Measured: 6 months periods from 2018 to 2029
Change in subject body mass index (BMI).
Defined as Weight (kg) / height (m)2.
Measured: 6 months periods from 2018 to 2029
Change in obesity and overweight classification.
Body mass index categorized according to Centers for Disease Control \& Prevention groupings (i.e., normal, overweight, class 1 obesity, class 2 obesity, class 3 obesity)
Measured: 6 months periods from 2018 to 2029
Secondary outcomes (18)
Change in emergency department visits.
Total visits
Measured: 6 months periods from 2018 to 2029
Change in obesity-related emergency department visits.
Visit with obesity-related diagnosis code (E66.1-E66.3, Z68.30-768.45), metabolic syndrome, type 2 diabetes, chronic kidney disease, cardiovascular disease, osteoarthritis of the knee, depression, anxiety, metabolic dysfunction-associated steatohepatitis, nonalcoholic fatty liver disease \& steatohepatitis, obstructive sleep apnea, hyperlipidemia, hypertension, cerebrovascular disease, asthma, gastroesophageal reflux disease (GERD), or chronic obstructive pulmonary disease (COPD).
Measured: 6 months periods from 2018 to 2029
Change in non-obesity related emergency department visits.
Visit without any of the following: obesity-related diagnosis code (E66.1-E66.3, Z68.30-768.45), metabolic syndrome, type 2 diabetes, chronic kidney disease, cardiovascular disease, osteoarthritis of the knee, depression, anxiety, metabolic dysfunction-associated steatohepatitis, nonalcoholic fatty liver disease \& steatohepatitis, obstructive sleep apnea, hyperlipidemia, hypertension, cerebrovascular disease, asthma, gastroesophageal reflux disease (GERD), or chronic obstructive pulmonary disease (COPD).
Measured: 6 months periods from 2018 to 2029
Change in preventable emergency department visits.
Preventable visits include those that are:
- non-emergent (the patient's initial complaint, presenting symptoms, vital signs, medical history, and age indicated that immediate medical care was not required within 12 hours), or
- emergent/primary care treatable (based on information in the record, treatment was required within 12 hours, but care could have been provided effectively and safely in a primary care setting. The complaint did not require continuous observation, and no procedures were performed or resources used that are not available in a primary care setting), or
- preventable/avoidable (Emergency department care was required based on the complaint or procedures performed/resources used, but the emergent nature of the condition was potentially preventable/avoidable if timely and effective ambulatory care had been received during the episode of illness).
Measured: 6 months periods from 2018 to 2029
Change in non-preventable emergency department visits.
Non-preventable visits are defined as emergency department care was required and ambulatory care treatment could not have prevented the condition.
Measured: 6 months periods from 2018 to 2029
Change in inpatient admissions.
Total number of distinct hospitalizations (i.e. admissions).
Measured: 6 months periods from 2018 to 2029
Change in obesity-related inpatient admissions.
Total hospitalizations with obesity-related diagnosis code (E66.1-E66.3, Z68.30-768.45), metabolic syndrome, type 2 diabetes, chronic kidney disease, cardiovascular disease, osteoarthritis of the knee, depression, anxiety, metabolic dysfunction-associated steatohepatitis, nonalcoholic fatty liver disease \& steatohepatitis, obstructive sleep apnea, hyperlipidemia, hypertension, cerebrovascular disease, asthma, gastroesophageal reflux disease (GERD), or chronic obstructive pulmonary disease (COPD).
Measured: 6 months periods from 2018 to 2029
Change in non-obesity-related inpatient admissions.
Total hospitalizations without obesity-related diagnosis code (E66.1-E66.3, Z68.30-768.45), metabolic syndrome, type 2 diabetes, chronic kidney disease, cardiovascular disease, osteoarthritis of the knee, depression, anxiety, metabolic dysfunction-associated steatohepatitis, nonalcoholic fatty liver disease \& steatohepatitis, obstructive sleep apnea, hyperlipidemia, hypertension, cerebrovascular disease, asthma, gastroesophageal reflux disease (GERD), or chronic obstructive pulmonary disease (COPD).
Measured: 6 months periods from 2018 to 2029
Change in inpatient admissions that began in the emergency department.
Total hospitalizations where the subject was admitted from the emergency department.
Measured: 6 months periods from 2018 to 2029
Change in direct admit inpatient admissions
Total hospitalizations that were admitted directly from the community, i.e. not transferred from the emergency department.
Measured: 6 months periods from 2018 to 2029
Change in 30 day inpatient readmissions.
Count of hospital admissions (to any facility) occurring within 30 days of a hospital stay.
Measured: 6 months periods from 2018 to 2029
Change in outpatient visits.
Any in-person office visits with primary care, family medicine, internal medicine, or any specialty (including behavioral health); excludes phone visits. Total visits, as well as separated by obesity-related vs non-obesity related.
Measured: 6 months periods from 2018 to 2029
Change in obesity-related outpatient visits.
Total in-person office visits with primary care, family medicine, internal medicine, or any specialty (including behavioral health) with any of the following: obesity-related diagnosis code (E66.1-E66.3, Z68.30-768.45), metabolic syndrome, type 2 diabetes, chronic kidney disease, cardiovascular disease, osteoarthritis of the knee, depression, anxiety, metabolic dysfunction-associated steatohepatitis, nonalcoholic fatty liver disease \& steatohepatitis, obstructive sleep apnea, hyperlipidemia, hypertension, cerebrovascular disease, asthma, gastroesophageal reflux disease (GERD), or chronic obstructive pulmonary disease (COPD).
Excludes: phone visits.
Measured: 6 months periods from 2018 to 2029
Change in non-obesity-related outpatient visits
Total in-person office visits with primary care, family medicine, internal medicine, or any specialty (including behavioral health) without any of the following: obesity-related diagnosis code (E66.1-E66.3, Z68.30-768.45), metabolic syndrome, type 2 diabetes, chronic kidney disease, cardiovascular disease, osteoarthritis of the knee, depression, anxiety, metabolic dysfunction-associated steatohepatitis, nonalcoholic fatty liver disease \& steatohepatitis, obstructive sleep apnea, hyperlipidemia, hypertension, cerebrovascular disease, asthma, gastroesophageal reflux disease (GERD), or chronic obstructive pulmonary disease (COPD).
Excludes: phone visits.
Measured: 6 months periods from 2018 to 2029
Change in total medical spending.
All medical costs paid (inpatient, outpatient, emergency department, and rehabilitation costs).
Measured: 6 months periods from 2018 to 2029
Change in total pharmacy spending.
All pharmacy costs paid.
Measured: 6 months periods from 2018 to 2029
Change in total pharmacy spending excluding incretin-based medications.
All pharmacy costs excluding the cost of incretin obesity medications
Measured: 6 months periods from 2018 to 2029
Change in total spending on obesity-related complications
All medical costs paid where the claim is associated with any of the following: obesity-related diagnosis code (E66.1-E66.3, Z68.30-768.45), metabolic syndrome, type 2 diabetes, chronic kidney disease, cardiovascular disease, osteoarthritis of the knee, depression, anxiety, metabolic dysfunction-associated steatohepatitis, nonalcoholic fatty liver disease \& steatohepatitis, obstructive sleep apnea, hyperlipidemia, hypertension, cerebrovascular disease, asthma, gastroesophageal reflux disease (GERD), or chronic obstructive pulmonary disease (COPD).
Excludes: telehealth / phone visits.
Measured: 6 months periods from 2018 to 2029
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2026
- Study start1 Jan 2026
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Indiana UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 125,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Indiana University
- Sponsor type
- University, hospital or other
- Collaborators
- Eli Lilly and Company
- Responsible party
- Principal investigator, Joshua R. Vest, PhD, Indiana University
- Investigators
- Joshua R Vest, PhD, MPH, Principal investigator, Indiana University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07640139
- Sponsor's protocol ID
- 00855196
- Other IDs
- 26469
- Status last verified
- Jun 2026
- First submitted
- 3 Jun 2026
- Last updated
- 10 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Raw and derived data at the patient level will not be publicly posted due to our use of secondary data from privately held claims, electronic health records, and health information exchange systems. Because of data use restrictions among the participating employer organizations contributing claims to the analysis and because of the data use restrictions established by consortium agreements among the health system partners contributing EHR data to the project, patient-level data cannot be shared or disseminated beyond this project. Nevertheless, de-identified derived health information exchange data (only) at the patient-level used in this study may be shared with investigators whose formal requests are approved by the data owners. Requests can be sent to askRDS@regenstrief.org. Access to this data requires investigator support and a signed data access agreement between the Regenstrief Institute and the investigator's institution.
Study at a glance
From the registry record, last updated by the sponsor on 10 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
- ClinicalTrials.gov ID
- NCT07640139
- Acronym / sponsor ID
- 00855196
- Conditions
- Obesity
- Keywords
- GLP-1, Obesity medications, Incretin-based
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 125,000 participants (estimated)
- Lead sponsor
- Indiana UniversityUniversity, hospital or other
- Collaborators
- Eli Lilly and Company
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 10 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers. The main questions it aims to answer are:
- Is obesity medication usage is associated with reduced body mass index (BMI) and weight?
- Is obesity medication usage is associated with reduced utilization of emergency department and inpatient care or obesity-related conditions over time?
- Is obesity medication usage is associated with increased utilization of outpatient care over time?
- Is obesity medication usage is associated with slower growth in direct medical costs over time?
- Is obesity medication usage is associated with improvements in health measures?
- Is obesity medication usage associated with reduced workplace costs?
Researchers will compare individuals who have prescriptions for obesity medications to those without to see if differences in health and costs of care exist.
The study uses existing medical and pharmacy claims data.
Detailed description
Incretin-based therapies that work by mimicking the action of the natural hormone GLP-1 and GLP-1/GIP have garnered the most excitement and demonstrated promising results in the management of obesity. This project seeks to estimate the impact of incretin-based obesity medications on clinical and economic outcomes in real-world settings. It proposes to fill gaps in the current literature by focusing on patients from self-insured organizations, measuring direct and indirect costs, establishing a long-term cohort, and by merging claims with electronic health record (EHR) data for more comprehensive measures.
The impact of incretin-based obesity medications on clinical and economic outcomes will be assessed in a dynamic cohort design. The cohort will be drawn from the employees and their working age dependents of large, self-insured (or "self-funded") organizations in the state of Indiana (i.e., "employers"). Employer organizations agreeing to participate will provide medical and pharmacy claims as well as data on workplace performance (if available) from 2018-2029. The primary exposure of interest is documented receipt of any GLP-1 obesity medication (regardless of manufacturer or brand name). A series of fixed-effects regression models will estimate the association between exposure to incretin-based obesity medications and clinical, utilization, and cost outcomes. This dynamic cohort approach, 1) individuals and participating employer organizations may enter and exit the cohort over time and 2) individuals may switch between on or off exposure over time.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Persistent use of incretin-based obesity medication | – | Drug: Incretin-based therapies (GLP-1 and GLP-1/GIP)Persistent use is defined as continuous treatment with no gaps greater than 60 days between prescription fills. Discontinuation is defined as a gap exceeding 60 days following the expected end date of a prescription fill (based on days' supply). Exposure will be measured longitudinally from the index date until discontinuation or censoring. Days of supply will be calculated from pharmacy claims, and we will account for stockpiling by allowing early refills to extend coverage forward in time. If days' supply is missing, it will be imputed using prescribing guidelines or external data sources. |
| No documented receipt of incretin-based obesity medication during observation period | – | –Working-age adults (age 18 to 64) insured by participating Indiana-based employers that do not use any incretin-based obesity medication for weight loss. Identified by no claim for obesity medications (accounting for days supply and available refills). |
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Working-age adults and their adult dependents who receive their health insurance coverage from participating, self-insured Indiana employers.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Incretin-based therapies (GLP-1 and GLP-1/GIP)Also: Zepbound, Tirzepatide, Wegovy, SemaglutideDocumented receipt of any GLP-1 and GLP-1/GIP obesity medication during an observation period. | Drug | Persistent use of incretin-based obesity medication |
Primary outcome
Change in subject body weight.
Time frame: 6 months periods from 2018 to 2029
Measured in pounds.
Change in subject body mass index (BMI).
Time frame: 6 months periods from 2018 to 2029
Defined as Weight (kg) / height (m)2.
Change in obesity and overweight classification.
Time frame: 6 months periods from 2018 to 2029
Body mass index categorized according to Centers for Disease Control \& Prevention groupings (i.e., normal, overweight, class 1 obesity, class 2 obesity, class 3 obesity)
18 secondary outcomes
Change in emergency department visits.
Time frame: 6 months periods from 2018 to 2029
Change in obesity-related emergency department visits.
Time frame: 6 months periods from 2018 to 2029
Change in non-obesity related emergency department visits.
Time frame: 6 months periods from 2018 to 2029
Change in preventable emergency department visits.
Time frame: 6 months periods from 2018 to 2029
Change in non-preventable emergency department visits.
Time frame: 6 months periods from 2018 to 2029
Change in inpatient admissions.
Time frame: 6 months periods from 2018 to 2029
Change in obesity-related inpatient admissions.
Time frame: 6 months periods from 2018 to 2029
Change in non-obesity-related inpatient admissions.
Time frame: 6 months periods from 2018 to 2029
Change in inpatient admissions that began in the emergency department.
Time frame: 6 months periods from 2018 to 2029
Change in direct admit inpatient admissions
Time frame: 6 months periods from 2018 to 2029
Change in 30 day inpatient readmissions.
Time frame: 6 months periods from 2018 to 2029
Change in outpatient visits.
Time frame: 6 months periods from 2018 to 2029
Change in obesity-related outpatient visits.
Time frame: 6 months periods from 2018 to 2029
Change in non-obesity-related outpatient visits
Time frame: 6 months periods from 2018 to 2029
Change in total medical spending.
Time frame: 6 months periods from 2018 to 2029
Change in total pharmacy spending.
Time frame: 6 months periods from 2018 to 2029
Change in total pharmacy spending excluding incretin-based medications.
Time frame: 6 months periods from 2018 to 2029
Change in total spending on obesity-related complications
Time frame: 6 months periods from 2018 to 2029
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jun 2026.
- Individual participant dataSharing planned: No. Raw and derived data at the patient level will not be publicly posted due to our use of secondary data from privately held claims, electronic health records, and health information exchange systems. Because of data use restrictions among the participating employer organizations contributing claims to the analysis and because of the data use restrictions established by consortium agreements among the health system partners contributing EHR data to the project, patient-level data cannot be shared or disseminated beyond this project. Nevertheless, de-identified derived health information exchange data (only) at the patient-level used in this study may be shared with investigators whose formal requests are approved by the data owners. Requests can be sent to askRDS@regenstrief.org. Access to this data requires investigator support and a signed data access agreement between the Regenstrief Institute and the investigator's institution.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Joshua R Vest, PhD, MPH principal investigator
Indiana University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity, run by Indiana University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 10 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in subject body weight. (time frame: 6 months periods from 2018 to 2029). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2026.